--- title: "FRKJ released its first-quarter performance, with a net profit attributable to the parent company of 20.6216 million yuan, a year-on-year decrease of 67.38%" type: "News" locale: "en" url: "https://longbridge.com/en/news/237424072.md" description: "FRKJ released its Q1 2025 performance report, with operating revenue of 561 million yuan, a year-on-year increase of 17.32%. However, the net profit attributable to shareholders of the listed company was 20.6216 million yuan, a year-on-year decrease of 67.38%; the net profit after deducting non-recurring gains and losses was 16.8035 million yuan, a year-on-year decrease of 60.42%. The basic earnings per share were 0.0268 yuan/share" datetime: "2025-04-24T15:34:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/237424072.md) - [en](https://longbridge.com/en/news/237424072.md) - [zh-HK](https://longbridge.com/zh-HK/news/237424072.md) generator: "portal-rs" --- # FRKJ released its first-quarter performance, with a net profit attributable to the parent company of 20.6216 million yuan, a year-on-year decrease of 67.38% According to the Zhitong Finance APP, FRKJ (603327.SH) released its first-quarter report for 2025. The company's first-quarter operating revenue was 561 million yuan, a year-on-year increase of 17.32%; the net profit attributable to shareholders of the listed company was 20.6216 million yuan, a year-on-year decrease of 67.38%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 16.8035 million yuan, a year-on-year decrease of 60.42%; basic earnings per share were 0.0268 yuan/share ### Related Stocks - [603327.CN](https://longbridge.com/en/quote/603327.CN.md) ## Related News & Research - [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md) - [Jiangsu Expressway schedules interim results presentation via telephone video conference](https://longbridge.com/en/news/296498702.md) - [KINGSOFT Interim Net Profit Up 100.8% YoY to RMB1.639 Billion; No Interim Dividend](https://longbridge.com/en/news/296417569.md) - [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md) - [Frozen blueberries recall categorized under FDA's highest Class I risk level](https://longbridge.com/en/news/296506599.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**